Therapy of untreated local advanced or metastatic renal cell carcinoma: Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 – AN 36/15 of the AUO);Therapie des unbehandelten lokal fortgeschrittenen oder metastasierten Nierenzellkarzinoms: Randomisierte offene Phase-III-Studie von Nivolumab kombiniert mit Ipilimumab- vs. Sunitinib-Monotherapie bei Patienten mit unbehandeltem, lokal fortgeschrittenem oder metastasiertem Nierenzellkarzinom (CheckMate 214 – AN36/15 der AUO)

Urologe

Volumn 54, Issue 10, 2015, Pages 1443-1445

  Rexer, H ^a  

^a MeckEvidence   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; HUMAN; KIDNEY METASTASIS; MONOTHERAPY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIAL; FEMALE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944158439     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-015-3946-5     Document Type: Article

References (8)

1. Schmiedinger M, Bellmunt J (2010) Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 36:416–424
2. Motzer RJ, Hutson TE, McCann L et al (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370:1769–1780
3. Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731
4. Motzer RJ, Escudier B, Oudard S et al (2014) Phase II randomized trial comparing sequential first-line everolimus and second-line Sunitinib versus first-line Sunitinib and second-line Everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32:2765–2772
5. Postow MA, Callahan MK, Wolchok JD (2014) Immune checkpoint blockade in cancer therapy. J Clin Oncol 32: 1020–1030. doi:10.1200/JCO.2014.59.4358
6. Michel MS, Vervenne W, de Santis M et al (2014) SWITCH study of efficacy and safety of Sorafenib/Sunitinib vs. Sunitinib/Sorafenib in the treatment of mRCC. J Clin Oncol 32(Suppl 4):393
7. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363:711–723
8. Plimack ER, Hammers HJ, Rini BI et al (2015) Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). Clin J Oncol 33(Suppl):4553